Table 5.
MTHFR A1298C and breast cancer survival
| Person-years1 | # events2 | HR (95% CI)3 | p-value | |
| A1298C genotype (n = 198) | ||||
| A/A | 1 | |||
| A/C or C/C | 873 | 46 | 2.05 (1.05–4.00) | 0.03 |
| ER-negative (n = 84) | ||||
| A/A | 1 | |||
| A/C or C/C | 352 | 29 | 2.70 (1.17–6.23) | 0.02 |
| ER-positive (n = 114) | ||||
| A/A | 1 | |||
| A/C or C/C | 521 | 17 | 1.39 (0.43–4.48) | 0.58 |
| African-American (n = 121) | ||||
| A/A | 1 | |||
| A/C or C/C | 520 | 29 | 1.57 (0.70–3.56) | 0.28 |
| Caucasian (n = 77) | ||||
| A/A | 1 | |||
| A/C or C/C | 352 | 17 | 6.28 (1.25–31.7) | 0.03 |
| No Chemotherapy (n = 81) | ||||
| A/A | 1 | |||
| A/C or C/C | 394 | 13 | 7.50 (1.49–37.7) | 0.01 |
| Chemotherapy (n = 117) | ||||
| A/A | 1 | |||
| A/C or C/C | 479 | 33 | 1.62 (0.76–3.46) | 0.21 |
1 Time at risk in person-years. 2 Number of deaths due to breast cancer. 3 Cox Proportional-Hazards regression with adjustments for age at diagnosis, race, C677T, BMI, estrogen receptor, TNM stage, and chemotherapy.